FunPep Inkomsten in het verleden
Verleden criteriumcontroles 0/6
FunPep has been growing earnings at an average annual rate of 31%, while the Biotechs industry saw earnings growing at 10.5% annually. Revenues have been declining at an average rate of 100% per year.
Belangrijke informatie
31.0%
Groei van de winst
41.6%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 31.9% |
| Inkomstengroei | -100.0% |
| Rendement op eigen vermogen | -33.9% |
| Nettomarge | n/a |
| Volgende winstupdate | 14 Nov 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe FunPep geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -727 | 265 | 455 |
| 31 Mar 24 | 0 | -760 | 267 | 484 |
| 31 Dec 23 | 0 | -933 | 267 | 680 |
| 31 Dec 22 | 1 | -1,172 | 222 | 912 |
Kwaliteitswinsten: 4881 is currently unprofitable.
Groeiende winstmarge: 4881 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Unable to establish if 4881's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Versnelling van de groei: Unable to compare 4881's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 4881 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Rendement op eigen vermogen
Hoge ROE: 4881 has a negative Return on Equity (-33.88%), as it is currently unprofitable.